Pharmaceutical Technology1 天
Treprostinil by United Therapeutics for Idiopathic Pulmonary Fibrosis: Likelihood of Approval
Treprostinil is under clinical development by United Therapeutics and currently in Phase III for Idiopathic Pulmonary Fibrosis.
Pharmaceutical Technology1 天
Ralinepag XR by United Therapeutics for Pulmonary Arterial Hypertension: Likelihood of Approval
Ralinepag XR is under clinical development by United Therapeutics and currently in Phase III for Pulmonary Arterial Hypertension.
pulmonologyadvisor8 天
In PAH, Early Use of Parenteral Prostacyclin Therapy Is Beneficial
At initiation of parenteral prostacyclin therapy, 62% of patients had intermediate-high COMPERA 2.0 risk status, whereas at ...
Taiwan News12 天
Pulmonary Arterial Hypertension (PAH) Market 2025 Statistics, Industry Share, Latest Trends ...
As the global economy recovers in 2021 and the supply of the industrial chain improves, the Pulmonary Arterial Hypertension (PAH) market will undergo major changes. According to the latest research, ...
Common pain reliever could cause medical complications in some people over 65, study suggests
A new study suggests that acetaminophen, also known as Tylenol, can cause complications in some people over age 65. Drs. Marc ...
Medscape22 天
Pharmacologic Treatments for Pulmonary Hypertension
Future Cardiol. 2013;9(3):335-349. Research into prostacyclin analogs for the treatment of WHO Group 2 PH has been limited, likely due to the early termination of the FIRST trial. [55] This study ...
manilatimes23 天
First FDA-approved treatment for severe frostbite now commercially available in the US
Aurlumyn™ is a prostacyclin mimetic and acts as a vasodilator (a drug that opens blood vessels) and inhibits platelet aggregation. Aurlumyn™ is indicated for the treatment of severe frostbite in ...